Seagen Wins Over English HTA Body With More Analyses & Lower Price For Tukysa
Executive Summary
NICE now says that Tukysa should be made available on the National Health Service for advanced or metastatic breast cancer, and notes that the drug also offers “real hope” to people whose cancer has spread to their brain.
You may also be interested in...
Sanofi Dives Back Into ADCs With Seagen Pact
Despite underwhelming sales for some cancer products and problems within the pipeline, Sanofi is forging ahead with an agreement for up to three ADCs with Seagen.
Scottish Funding OK For Breast Cancer Drugs Tukysa And Enhertu
As well as recommending Seagen’s Tukysa and Daiichi Sankyo/AstraZeneca’s Enhertu, the Scottish Medicines Consortium has given the green light to Leo Pharma’s Adtralza and a new lung cancer indication for AZ’s Tagrisso. Meanwhile, Alexion has failed to make a submission to HTAs in both Scotland and England for a specific indication for Soliris.
Blow For Seagen As England Rejects Funding For Advanced Breast Cancer Drug Tukysa
England’s health technology assessment body said it would continue to work with Seagen to address the reasons why its newly published draft guidance has recommended against using Tukysa on the National Health Service.